{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:21:10Z","timestamp":1772720470705,"version":"3.50.1"},"reference-count":157,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2467,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/jto.0b013e3181951ce8","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T06:09:24Z","timestamp":1264572564000},"page":"411-425","source":"Crossref","is-referenced-by-count":16,"title":["In Arrayed Ranks: Array Technology in the Study of Mesothelioma"],"prefix":"10.1016","volume":"4","author":[{"given":"Steven G.","family":"Gray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181951ce8_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","article-title":"Malignant pleural mesothelioma: a comprehensive review","volume":"13","author":"Ismail-Khan","year":"2006","journal-title":"Cancer Control"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajim.20246","article-title":"Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model","volume":"49","author":"Murayama","year":"2006","journal-title":"Am J Ind Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib5","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1016\/j.ejca.2006.07.011","article-title":"Biology and management of malignant pleural mesothelioma","volume":"42","author":"Zucali","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","article-title":"Advances in the systemic therapy of malignant pleural mesothelioma","volume":"5","author":"Fennell","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"Suppl 2","key":"10.1097\/JTO.0b013e3181951ce8_bib7","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.lungcan.2006.09.011","article-title":"Malignant pleural mesothelioma: a new standard of care","volume":"54","author":"Stahel","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0b013e328302851d","article-title":"Malignant mesothelioma 2008","volume":"14","author":"Zervos","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tig.2005.12.005","article-title":"Reliability and reproducibility issues in DNA microarray measurements","volume":"22","author":"Draghici","year":"2006","journal-title":"Trends Genet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05616","article-title":"A genome-wide association study identifies novel risk loci for type 2 diabetes","volume":"445","author":"Sladek","year":"2007","journal-title":"Nature"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nrg1901","article-title":"Highly parallel genomic assays","volume":"7","author":"Fan","year":"2006","journal-title":"Nat Rev Genet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tig.2003.12.008","article-title":"Genomic microarrays in the spotlight","volume":"20","author":"Mantripragada","year":"2004","journal-title":"Trends Genet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2144\/000112322","article-title":"High-throughput methods of regulatory element discovery","volume":"41","author":"Hudson","year":"2006","journal-title":"Biotechniques"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib14","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/0008-5472.CAN-06-0276","article-title":"ChIP-chip comes of age for genome-wide functional analysis","volume":"66","author":"Wu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib15","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1073\/pnas.0306641101","article-title":"Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation","volume":"101","author":"Kondo","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib16","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1093\/emboj\/cdg604","article-title":"Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer","volume":"22","author":"Ballestar","year":"2003","journal-title":"Embo J"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jhep.2004.05.018","article-title":"Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells","volume":"41","author":"Chiba","year":"2004","journal-title":"J Hepatol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib18","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1371\/journal.pmed.0030486","article-title":"A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies","volume":"3","author":"Shames","year":"2006","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib19","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van 't Veer","year":"2002","journal-title":"Nature"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00432-004-0574-7","article-title":"Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers","volume":"130","author":"Onda","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1349-7006.2004.tb02206.x","article-title":"Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray","volume":"95","author":"Nagahata","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clinbiochem.2004.05.002","article-title":"State of the science: molecular classifications of breast cancer for clinical diagnostics","volume":"37","author":"Robison","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/14622416.5.6.611","article-title":"Using microarrays to predict resistance to chemotherapy in cancer patients","volume":"5","author":"Lee","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2174\/1568026043387610","article-title":"The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems","volume":"4","author":"Villeneuve","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib26","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.ejca.2004.05.020","article-title":"Genomic and proteomic technologies for individualisation and improvement of cancer treatment","volume":"40","author":"Wulfkuhle","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/14737159.4.6.831","article-title":"Laser capture microdissection, microarrays and the precise definition of a cancer cell","volume":"4","author":"Player","year":"2004","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14737159.4.6.761","article-title":"QA\/QC: challenges and pitfalls facing the microarray community and regulatory agencies","volume":"4","author":"Shi","year":"2004","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.surg.2004.05.041","article-title":"Application of microarray profiling to clinical trials in cancer","volume":"136","author":"Olson","year":"2004","journal-title":"Surgery"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/sj.clpt.6100053","article-title":"The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program","volume":"81","author":"Orr","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nbt0906-1105","article-title":"Impact of microarray data quality on genomic data submissions to the FDA","volume":"24","author":"Frueh","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib32","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nbt1239","article-title":"The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements","volume":"24","author":"Shi","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2006.11.005","article-title":"Arrays of hope","volume":"127","author":"Strauss","year":"2006","journal-title":"Cell"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0014-5793(00)01913-X","article-title":"Differential gene expression in mesothelioma","volume":"480","author":"Rihn","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M","article-title":"Gene expression profiling of malignant mesothelioma cell lines: cDNA array study","volume":"91","author":"Kettunen","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib36","first-page":"39","article-title":"Stathmin is overexpressed in malignant mesothelioma","volume":"27","author":"Kim","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib37","first-page":"3539","article-title":"Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma","volume":"63","author":"Ramos-Nino","year":"2003","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2164-8-62","article-title":"Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines","volume":"8","author":"Nymark","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib39","series-title":"Malignant Pleural Mesotheliomaed","first-page":"129","article-title":"Carcinogenic mechanisms in mesothelioma: effects of asbestos on cell signalling events, transcription factors, and inflammatory cytokines","author":"Swain","year":"2006"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib40","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0169-5002(03)91736-3","article-title":"Microarray analysis of mesothelial cells treated with crocidolite, erionite, IL-1beta and TNF-alpha","volume":"41","author":"Swain","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib41","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/carcin\/bgh276","article-title":"L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray","volume":"26","author":"Kettunen","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","article-title":"Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients","volume":"97","author":"Usami","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib44","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature03799","article-title":"Genes that mediate breast cancer metastasis to lung","volume":"436","author":"Minn","year":"2005","journal-title":"Nature"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib45","doi-asserted-by":"crossref","first-page":"16472","DOI":"10.1073\/pnas.0605752103","article-title":"The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib46","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/cncr.22706","article-title":"Manipulating the chemokine-chemokine receptor network to treat cancer","volume":"109","author":"Ruffini","year":"2007","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib47","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1378\/chest.109.3_Supplement.21S","article-title":"Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8","volume":"109","author":"Antony","year":"1996","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2741\/1579","article-title":"The role of interleukin-8 in cancer cells and microenvironment interaction","volume":"10","author":"Yuan","year":"2005","journal-title":"Front Biosci"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib49","first-page":"187","article-title":"Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model","volume":"11","author":"Galffy","year":"1999","journal-title":"Oncol Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib50","first-page":"367","article-title":"Interleukin 8: an autocrine growth factor for malignant mesothelioma","volume":"59","author":"Galffy","year":"1999","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib51","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.molimm.2007.01.022","article-title":"TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance","volume":"44","author":"He","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib52","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbrc.2007.12.030","article-title":"TLR4 signaling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20","volume":"366","author":"Wang","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.1810","article-title":"Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling","volume":"207","author":"Sun","year":"2005","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib54","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1096-9896(199607)179:3<266::AID-PATH592>3.0.CO;2-Y","article-title":"Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma","volume":"179","author":"Ruco","year":"1996","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0008-8749(03)00058-3","article-title":"Activation of vascular endothelial cells by IL-1alpha released by epithelial cells infected with respiratory syncytial virus","volume":"221","author":"Chang","year":"2003","journal-title":"Cell Immunol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib56","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/(SICI)1097-0215(19960917)67:6<856::AID-IJC16>3.0.CO;2-#","article-title":"IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice","volume":"67","author":"Chirivi","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib57","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jcem.87.4.8431","article-title":"Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta","volume":"87","author":"St-Pierre","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/dnares\/5.6.355","article-title":"Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro","volume":"5","author":"Nagase","year":"1998","journal-title":"DNA Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib59","first-page":"4963","article-title":"Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma","volume":"62","author":"Gordon","year":"2002","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib60","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib61","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-04-2181","article-title":"Validation of genomics-based prognostic tests in malignant pleural mesothelioma","volume":"11","author":"Gordon","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib62","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","article-title":"Gene expression profiles predict survival and progression of pleural mesothelioma","volume":"10","author":"Pass","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib63","doi-asserted-by":"crossref","first-page":"W206","DOI":"10.1093\/nar\/gkm327","article-title":"Onto-Tools: new additions and improvements in 2006","volume":"35","author":"Khatri","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib64","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib65","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1172\/JCI23412","article-title":"Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer","volume":"115","author":"Glinsky","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib66","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1378\/chest.125.5.1843","article-title":"Gene expression profiling identifies matriptase overexpression in malignant mesothelioma","volume":"125","author":"Hoang","year":"2004","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib67","first-page":"3080","article-title":"Gene expression profiling of malignant mesothelioma","volume":"9","author":"Singhal","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biochi.2003.11.008","article-title":"Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells","volume":"86","author":"Mohr","year":"2004","journal-title":"Biochimie"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbadis.2003.10.007","article-title":"Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray","volume":"1688","author":"Mohr","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib70","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib71","doi-asserted-by":"crossref","first-page":"14713","DOI":"10.1073\/pnas.94.26.14713","article-title":"Identification of semaphorin E as a non-MDR drug resistance gene of human cancers","volume":"94","author":"Yamada","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib72","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ijc.21160","article-title":"Wnt2 as a new therapeutic target in malignant pleural mesothelioma","volume":"117","author":"Mazieres","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib73","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/carcin\/23.6.1017","article-title":"Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma","volume":"23","author":"Gordon","year":"2002","journal-title":"Carcinogenesis"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/path.2121","article-title":"Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma","volume":"211","author":"Gordon","year":"2007","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib75","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-06-0669","article-title":"Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura","volume":"12","author":"Schrump","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cancergencyto.2006.04.011","article-title":"Cytogenetic and molecular genetic changes in malignant mesothelioma","volume":"170","author":"Musti","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.ejhg.5201531","article-title":"Recent advances in array comparative genomic hybridization technologies and their applications in human genetics","volume":"14","author":"Lockwood","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib78","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1101\/gr.2012304","article-title":"High-resolution analysis of DNA copy number using oligonucleotide microarrays","volume":"14","author":"Bignell","year":"2004","journal-title":"Genome Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib79","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-04-4603","article-title":"Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis","volume":"65","author":"Zhao","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cancergencyto.2006.05.002","article-title":"High-resolution analysis of 9p loss in human cancer cells using single nucleotide polymorphism-based mapping arrays","volume":"170","author":"Pei","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib81","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib82","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib83","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/gcc.20475","article-title":"Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines","volume":"46","author":"Zanazzi","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/omi.2006.10.311","article-title":"Microarrays as validation strategies in clinical samples: tissue and protein microarrays","volume":"10","author":"Aguilar-Mahecha","year":"2006","journal-title":"OMICS"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib85","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2144\/04361RV01","article-title":"Tissue microarrays","volume":"36","author":"Simon","year":"2004","journal-title":"Biotechniques"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399403006781","article-title":"Tissue microarray (TMA) applications: implications for molecular medicine","volume":"5","author":"Simon","year":"2003","journal-title":"Expert Rev Mol Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/14789450.2.3.325","article-title":"Tissue microarrays: bridging the gap between research and the clinic","volume":"2","author":"Braunschweig","year":"2005","journal-title":"Expert Rev Proteomics"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib88","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.prp.2006.04.003","article-title":"Multitissue array review: a chronological description of tissue array techniques, applications and procedures","volume":"202","author":"Eguiluz","year":"2006","journal-title":"Pathol Res Pract"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib89","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/path.2120","article-title":"Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma","volume":"211","author":"Gordon","year":"2007","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib90","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib91","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib92","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib93","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdi004","article-title":"Proteomic analysis for the early detection and rational treatment of cancer\u2013realistic hope?","volume":"16","author":"Posadas","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib94","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/14712598.6.8.833","article-title":"Antibody microarray-based oncoproteomics","volume":"6","author":"Borrebaeck","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib95","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1373\/clinchem.2005.059592","article-title":"Antibody arrays: technical considerations and clinical applications in cancer","volume":"52","author":"Sanchez-Carbayo","year":"2006","journal-title":"Clin Chem"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib96","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrd2006","article-title":"Multiplexed protein measurement: technologies and applications of protein and antibody arrays","volume":"5","author":"Kingsmore","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib97","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.copbio.2006.06.013","article-title":"Applications of antibody array platforms","volume":"17","author":"Haab","year":"2006","journal-title":"Curr Opin Biotechnology"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib98","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1074\/mcp.R600010-MCP200","article-title":"Tumor-associated antigen arrays for the serological diagnosis of cancer","volume":"5","author":"Casiano","year":"2006","journal-title":"Mol Cell Proteomics"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib99","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63739-X","article-title":"Proteomic analysis of exosomes secreted by human mesothelioma cells","volume":"164","author":"Hegmans","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","article-title":"Proteomic analysis of exosomes isolated from human malignant pleural effusions","volume":"31","author":"Bard","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib101","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1440-1827.2006.02024.x","article-title":"Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers","volume":"56","author":"Maeda","year":"2006","journal-title":"Pathol Int"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib102","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1097\/JTO.0b013e3181951ce8_bib103","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.lungcan.2005.03.020","article-title":"Soluble mesothelin-related protein\u2013a blood test for mesothelioma","volume":"49","author":"Robinson","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib106","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib107","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1078-0432.CCR-07-1613","article-title":"Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for N-ERC\/Mesothelin Increases its Potential as a Useful Serum Tumor Marker for Mesothelioma","volume":"14","author":"Shiomi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib108","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200802-258OC","article-title":"Soluble Mesothelin-Related Protein (SMRP) in an asbestos exposed population the dust diseases board cohort study","volume":"178","author":"Park","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib109","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1349-7006.2006.00246.x","article-title":"Novel ELISA system for detection of N-ERC\/mesothelin in the sera of mesothelioma patients","volume":"97","author":"Shiomi","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib110","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin Chem"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib111","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib112","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus i.v. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib113","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib114","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/jcb.20828","article-title":"Cellular and molecular parameters of mesothelioma","volume":"98","author":"Ramos-Nino","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2407-6-207","article-title":"Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system","volume":"6","author":"Vordermark","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1055-9965.EPI-07-0607","article-title":"Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study","volume":"17","author":"Amati","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib117","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1556-0864(15)31534-3","article-title":"Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition","volume":"1","author":"Carbone","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib118","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ijc.22425","article-title":"SV40 and human cancer: a review of recent data","volume":"120","author":"Shah","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib119","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1158\/0008-5472.CAN-05-0127","article-title":"SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure","volume":"65","author":"Cacciotti","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib120","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1158\/0008-5472.CAN-04-2219","article-title":"SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study","volume":"65","author":"Cristaudo","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib121","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1349-7006.2006.00171.x","article-title":"Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan","volume":"97","author":"Aoe","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib122","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/0008-5472.CAN-04-2461","article-title":"Evidence against a role for SV40 in human mesothelioma","volume":"65","author":"Manfredi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib123","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(04)17102-X","article-title":"Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids","volume":"364","author":"Lopez-Rios","year":"2004","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib124","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/ijc.22592","article-title":"Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples","volume":"120","author":"Kjaerheim","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib125","first-page":"109","article-title":"Polio vaccines, SV40 and human tumours, an update on false positive and false negative results","volume":"123","author":"Elmishad","year":"2006","journal-title":"Dev Biol (Basel)"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib126","doi-asserted-by":"crossref","first-page":"10120","DOI":"10.1158\/0008-5472.CAN-05-1911","article-title":"SV40 detection in human tumor specimens","volume":"65","author":"Carbone","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib127","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1158\/0008-5472.CAN-07-2232","article-title":"SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma","volume":"67","author":"Comar","year":"2007","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib128","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1158\/0008-5472.CAN-05-4668","article-title":"A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent","volume":"66","author":"Robinson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib129","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1158\/0008-5472.CAN-05-3727","article-title":"SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells","volume":"67","author":"Pietruska","year":"2007","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib130","doi-asserted-by":"crossref","first-page":"14128","DOI":"10.1073\/pnas.0604544103","article-title":"Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters","volume":"103","author":"Kroczynska","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib131","doi-asserted-by":"crossref","first-page":"9754","DOI":"10.1073\/pnas.171209998","article-title":"Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification","volume":"98","author":"Takahashi","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib132","first-page":"2858","article-title":"Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules","volume":"53","author":"Lee","year":"1993","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib133","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cancergencyto.2003.10.006","article-title":"Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment","volume":"152","author":"Kettunen","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib134","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/0008-5472.CAN-04-1898","article-title":"Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes","volume":"64","author":"Hoang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib135","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/1078-0432.CCR-0901-3","article-title":"Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells","volume":"10","author":"Nguyen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib136","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbrc.2003.12.074","article-title":"Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation","volume":"314","author":"Neuzil","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib137","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1165\/ajrcmb.25.5.4539","article-title":"Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma","volume":"25","author":"Cao","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib138","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002371-200103000-00010","article-title":"Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1","volume":"24","author":"Weiser","year":"2001","journal-title":"J Immunother"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib139","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib140","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib141","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLC.2006.n.003","article-title":"Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid","volume":"7","author":"Krug","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib142","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2006.06.017","article-title":"Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma","volume":"54","author":"Fischer","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib143","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.bbrc.2006.02.084","article-title":"Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma","volume":"342","author":"Batra","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib144","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.lungcan.2004.08.003","article-title":"Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung","volume":"47","author":"Tsou","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0169-5002(02)00178-2","article-title":"Inactivation of p16INK4a expression in malignant mesothelioma by methylation","volume":"38","author":"Wong","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib146","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/carcin\/bgn059","article-title":"Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma","volume":"29","author":"Christensen","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib147","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2004.10.003","article-title":"Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions","volume":"48","author":"Falleni","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib148","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nbt1017","article-title":"Systems biology in drug discovery","volume":"22","author":"Butcher","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib149","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1471-2407-8-236","article-title":"National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research","volume":"8","author":"Amin","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2407-8-91","article-title":"The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue Bank","volume":"8","author":"Mohanty","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib151","first-page":"687","article-title":"Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides","volume":"1","author":"Xia","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib152","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jcb.10742","article-title":"Phenylbutyrate decreases type I collagen production in human lung fibroblasts","volume":"91","author":"Rishikof","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib153","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-05-0344","article-title":"Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2","volume":"11","author":"Bali","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib154","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.042903","article-title":"Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin","volume":"304","author":"De Schepper","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib155","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1158\/0008-5472.CAN-06-1950","article-title":"SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases","volume":"66","author":"Thangaraju","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib156","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0006-2952(03)00411-8","article-title":"Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors","volume":"66","author":"Sasakawa","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1097\/JTO.0b013e3181951ce8_bib157","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2005.05.040","article-title":"SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines","volume":"237","author":"Ryu","year":"2006","journal-title":"Cancer Lett"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415309977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415309977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T11:00:42Z","timestamp":1558782042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415309977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1556086415309977"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181951ce8","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}